-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although symptomatic presentation and disease progression vary among patients with idiopathic Parkinson's disease (iPD), the underlying histopathological changes and the temporal order of regions involved are relatively stereotyped
Figure 1: Paper cover image
In this context, the predominance of PDRP can be understood from the regional order of histopathological changes in iPD that Braak originally described
Likewise, iPD patients' delta was compared to iRBD19 subjects as well as PD genotypes associated with LRRK2-G2019S mutation and GBA1 variant patients associated with slower and faster disease progression
Figure 2: The results of the paper
Delta was abnormally elevated in each of the four iPD samples (P < 0.
The PDRP advantage was also present in gPD, with higher values in patients with GBA1 variant compared with the less aggressive LRRK2-G2019S mutation (P = 0.
This trend was not observed in patients with atypical parkinsonism, who were accurately distinguished from iPD based on PDRP expression and delta (area under the curve = 0.
The significance of this study lies in the discovery that PDRP benefits, quantified by delta, can detect the diffusion of dysfunction from motor networks to cognitive networks in PD patients
